Medically reviewed by Mark Strehlow, MD, Medical Director — November 2026
KLOW is a product name, not a molecule: a blend sold as one vial for injection, said to hold four peptides (GHK-Cu, KPV, BPC-157 and TB-500) and promoted for tissue repair, inflammation, gut problems and skin. No study has tested the blend in people, in animals or in cells; the research is on its ingredients one at a time, mostly in animals and cells, and in the one animal study of two of them together, the pair did no better than either alone. In people, KPV has no published study by any route, and two of the four (BPC-157 and TB-500) have been injected together in only three patients, with three other drugs and no comparison group.
This review covers what is sold under the name, where such blends stand with the FDA, and what is known about the four together. Each ingredient has its own review in our peptide library. Our providers prescribe some of the peptides reviewed in this library, and we earn money from that care.
At a glance
- FDA status
- Not FDA-approved, and outside the FDA’s and HHS’s compounding policies.
- Evidence in people
- None for the blend. KPV, one of its four ingredients, has no published study in people.
- The claim you’ve heard
- The four work better together: not tested. In rats, one pair did no better than either alone.
- Doses tested in people
- None for the blend, at any ratio or by any route.
- Sport
- BPC-157 and TB-500 are prohibited at all times on WADA’s 2026 and 2027 Lists.
What KLOW is
KLOW has no sequence, formula or official monograph of its own. A vial holds whatever its seller or pharmacy put in it, and nobody defines the name.
What sellers and clinics say is in it. The composition stated most often is a freeze-dried 80 mg vial: 50 mg of GHK-Cu and 10 mg each of KPV, BPC-157 and TB-500. Others differ. One seller’s four listed amounts add up to 81.58 mg beside a stated total of 80 mg, and one clinic’s page says “The exact formulation varies by compounding pharmacy and prescribing physician”.
Which molecules, exactly, no page we read says. Pages call one ingredient “TB-500 (TB4)” or “a synthetic form of thymosin beta-4”; TB-500 (seven amino acids) and thymosin beta-4 (the 43-amino-acid protein it is taken from) are different molecules. None says which copper complex the GHK-Cu is, or whether the KPV and the BPC-157 are the free base or the acetate salt.
The four ingredients, each with its own review:
- GHK-Cu: three amino acids bound to a copper ion.
- KPV: three amino acids, the last three of the hormone alpha-MSH.
- BPC-157: a synthetic peptide 15 amino acids long.
- TB-500: seven amino acids, positions 17 to 23 of thymosin beta-4, with an acetyl group added.
The name. Pages describe KLOW as GLOW, an older blend of GHK-Cu, BPC-157 and TB-500, with KPV added.
Where it stands with the FDA
Status checked: November 19, 2026.
In plain words: a compounded injection that mixes two or more of BPC-157, TB-500, GHK-Cu and KPV is not an FDA-approved medicine. HHS, the federal department the FDA belongs to, has a draft policy on compounding certain single peptides, and the FDA has an interim policy of its own; a blend like KLOW falls outside both.
As of November 19, 2026, compounded injections that combine two or more of these peptides are not FDA-approved, and they fall outside HHS’s draft interim policy of October 30, 2026, which applies only when “the compounded drug product contains only a single Active Pharmaceutical Ingredient (API) listed in Appendix A.” They are outside the FDA’s own Category 1 policy as well. The FDA’s guidance says a drug compounded from a substance outside section 503A’s three conditions “is not eligible for the exemptions in section 503A and may violate the FD&C Act.”
Compounding means a pharmacist or physician makes a medicine for one identified patient on a prescription; section 503A is the federal law that sets its conditions, and the FD&C Act is the federal Food, Drug, and Cosmetic Act.
Why a blend falls outside HHS’s draft policy
In announcing the policy, HHS said it “does not intend to take enforcement action” against a state-licensed pharmacy or licensed physician compounding a drug from one of six listed peptides. BPC-157, KPV and TB-500 are on the list and GHK-Cu is not, but the policy document applies only “when all of the following circumstances are present”, and a vial of these four falls outside on three counts:
- More than one active ingredient. HHS’s reason for its single-ingredient condition: “It will be easier to attribute adverse events or clinical outcomes to a specific substance”.
- GHK-Cu by injection. It is not on HHS’s list and is in no FDA category; the FDA’s Category 1 entry reads “GHK-Cu (except for injectable routes of administration)”.
- KPV by injection. HHS’s policy names KPV acetate for “topical and oral dosage forms” and no injectable form.
HHS’s notice calls the policy a draft and says it “does not establish any rights for any person and is not binding on HHS or the public”. It is not FDA approval.
Sport
The blend, as described, contains two substances named on WADA’s Prohibited List, BPC-157 (class S0) and TB-500 (class S2.3), both prohibited at all times on the 2026 and 2027 Lists. GHK-Cu and KPV are not named on either List, and WADA does not state whether its class for non-approved substances (S0) reaches them. Its note on the 2027 List says: “Even if a peptide is not specifically named on the List, utmost caution should be taken as it may still be prohibited and may be harmful to health.”
Claims you’ll see, and why sources disagree
Why pages about KLOW disagree with each other, and with the research:
- Four separate stories are added up and called synergy. One clinic’s page says of the four that “their synergy is where the formulation truly excels.” Its reference list names papers on single peptides; none is on the combination.
- Parent molecules stand in for the ingredients. The same list names papers on alpha-MSH and thymosin beta-4, the molecules KPV and TB-500 are taken from. Each is a different substance.
- A federal policy is misread. One company’s page presents HHS’s draft policy as an FDA policy under which three of the four can be compounded. It is HHS’s, and a draft; it states only what HHS “does not intend” to act against, and it applies to single-ingredient products, not to a blend.
“Not tested in people” is not the same as “doesn’t work”. It means nobody knows, and it cuts both ways: the blend has not been shown to help people, and it has not been shown to be safe for them.
| Claim | Evidence for the blend | What exists for a pair or one ingredient, with its level |
|---|---|---|
| The four work better together (“synergy”) | None | Animal studies: in rats, one pair “did not confer additional benefits compared to either agent alone” |
| Calms inflammation, repairs the gut | None | KPV: lab studies and animal studies; never given to a person in a published study. BPC-157: tested in people in one small enema trial for ulcerative colitis, which did not show a difference from placebo on the FDA’s figures |
| Firmer skin, slower ageing | None | GHK-Cu on the skin: tested in people, weak support. By injection: not tested in people |
| Tendon, ligament and muscle recovery | None | BPC-157: animal and lab studies; one uncontrolled knee survey reported in people. TB-500: one rat tendon study |
| “Well tolerated” | Not established: no safety study of the blend exists | KPV: no data in people. BPC-157: about 83 people in published reports |
What the evidence consists of
Writing about KLOW mixes three kinds of evidence: studies of the blend itself, studies of two of the four given together, and studies of one ingredient alone, by one route. Only the first is evidence for KLOW.
The blend itself
There is none: no study in people, in animals or in cells, and no registered trial. Nor is there a study of any three of the four together, or of KPV with any of the others. We searched PubMed, Europe PMC and ClinicalTrials.gov on November 19, 2026; a study indexed nowhere we searched would have been missed.
Tested in people: one pilot, of BPC-157 with thymosin beta-4
No controlled study in people has given two of the four together. The nearest is a 2026 pilot (Majumdar and colleagues) of BPC-157 with thymosin beta-4, described in the paper as the 43-amino-acid protein; the paper never mentions TB-500. The two were given as separate injections, so this is not a study of TB-500, of KLOW or of any mixed vial.
At one centre in Cuba, five adults with a thoracic spinal cord injury had both injections under the skin weekly for 26 weeks, added to rehabilitation; five others, matched by injury level, had the same rehabilitation and no placebo injection. Nobody was randomized or blinded. Leg motor scores at 6 months were “29.4 ± 3.8 points” against “19.0 ± 3.5 points” (“exact two-sided p = 0.008”). The authors: “The magnitude of recovery in both arms markedly exceeds published natural-history and locomotor-training benchmarks, so these results must be treated as hypothesis-generating only.”
Much is unconfirmed. The registration the paper states was not found in the Cuban registry it names. The paper declares no competing interests, but its funding line reads “Funding: To be declared.”, and its acknowledgment thanks a company for providing the peptides; that the product was the full-length protein rests on an identity check reported without data. Its abstract and its table count side effects differently, and it places both peptides in WADA’s class S0, though WADA names thymosin beta-4 under S2.3. The journal is not indexed in PubMed, and how it reviewed the paper (received September 5, accepted September 25, 2026) is unconfirmed. The only other account is the authors’ own preprint review. With no group given one peptide alone, the pilot cannot show that two did more than one.
Reported in people: two uncontrolled reports
Neither tests a combination against its parts, and neither includes KPV. Only the first names TB-500.
| Report | People | What was given together | What happened | Limits |
|---|---|---|---|---|
| Froum and colleagues, 2026 | 3, with nerve injury after dental surgery | TB-500 and BPC-157 with three other drugs, weekly for 4 weeks | Near-complete return of sensation in all three | No comparison group. The authors: “causality cannot be established” |
| Lee and Padgett, 2021 | 4 of 16 with knee pain | BPC-157 into the knee joint, plus “TB4” | “75% showed significant improvement, but 25% had no relief of their knee pain” | Abstract read. No comparison group; “TB4” is named as thymosin beta-4, with no sequence or source |
Animal studies: one test of a pair against its parts
In a 2026 study (Biçer and colleagues; abstract read), 32 rats with a cut and repaired Achilles tendon were given BPC-157, a peptide named TB-500, both, or neither, by injection into the abdomen for four weeks. The authors conclude: “Combined BPC-157 and TB-500 treatment did not confer additional benefits compared to either agent alone.” They call the study “exploratory”; it used one dose of each peptide, and the abstract does not say which molecule its “synthetic thymosin beta-4 (TB-500)” was.
Each ingredient on its own
Almost all the research sits here, and none of it is evidence for the blend.
- GHK-Cu: tested in people only on the skin; no study in people of the injected peptide given alone.
- KPV: no study in people, by any route.
- BPC-157: two small enema trials and a few uncontrolled reports; nothing published in people on its use alone under the skin.
- TB-500: nothing published in people on the fragment injected under the skin or into muscle; the trials in people belong to thymosin beta-4, a different molecule.
Lab studies and how it is thought to work
For the blend, nothing has been tested. “Synergy” rests on each ingredient’s separate mechanism, none of which has been shown in a study in people. For two of them the FDA says the targets are unknown: “the molecular targets for BPC-157 have not been identified”, and those of KPV “remain unknown”.
Dosing: what has been tested, what is used, and what the reasoning supports
This section reports and reasons; it recommends nothing. No dose of KLOW has been tested in anyone, so no study has compared one dose with another, and no dose can be called optimal.
Doses tested in people
For the blend: none, at any ratio or by any route, in a published study in people or in a registered trial.
By injection under the skin, the route the blend is sold for, no ingredient given alone has a tested dose either. Each ingredient’s review gives what has been tested by other routes; for KPV, that is nothing.
One report gave two of the four together and states amounts: the three-case series (“TB-500 [10 mg]” and “BPC-157 [1 mg]” weekly for 4 weeks, injected under the lining of the mouth with three other drugs). The pilot gave BPC-157 under the skin beside thymosin beta-4, not TB-500, as separate injections (“weekly subcutaneous Tβ4 1.65 mg” and “BPC-157 0.8 mg” “for 26 consecutive weeks”). Neither is a dose of the blend, and neither compared amounts.
Doses in common use
These are amounts in circulation: practice that no trial set, reported so that you can see where they come from and how they compare with what has been studied. None is a tested dose or advice. They come from sellers’ pages, dosing websites and a forum; we found no compounding pharmacy’s prescriber material for this blend.
- Once a day, under the skin: every page that gives both a route and a frequency (two sellers’ help pages, a dosing website, a dosing-chart website). No study in people has used any schedule of the blend; the one pilot that gave BPC-157 under the skin, beside thymosin beta-4, gave it weekly.
- About 2 to 6 mg of total blend a day, in steps: a seller’s guide and a dosing website describe a schedule that rises from about 2 mg to about 6 mg a day and falls back to 4; a dosing-chart website labels “4.0 mg blend per injection” “MOST COMMON”. None cites a study in people, and no dose of the blend has been tested to compare them with.
- Per ingredient, by the dosing website’s breakdown: “~1.25 mg” to “~3.75 mg” of GHK-Cu and “~250 mcg” to “~750 mcg” each of the other three. A forum post starts lower (“1mg GHK-Cu / 0.2mg BPC / 0.2mg TB / 0.2mg KPV” daily). None of these amounts has been tested in people.
- Cycles: “4-6 weeks on, 2-4 weeks off” (the dosing website) or “8–12 weeks” (sellers’ pages). No study has followed anyone on the blend.
What the pharmacology supports, and what it doesn’t
- Amount. Not measured: any of the four, or copper, in blood or tissue after the mixture was given. Inferred: the ratio is fixed in the vial, so an amount chosen with one peptide in mind sets the other three.
- Frequency. Not measured in people: a half-life for any of the four by this route. Measured in animals: under 30 minutes for BPC-157 in rats and dogs; in horses, TB-500 became unquantifiable in the blood “between 6 and 10 hours” after a dose under the skin. Inferred: the copper differs, because it joins the body’s copper pool and is not short-lived in the same way. None of this supports one interval over another.
- Route and duration. Convention: under the skin, in cycles. Claimed and not confirmed: that breaks are needed because of “copper accumulation from GHK-Cu”; no study has measured copper levels after injected GHK-Cu.
- Monitoring. Inferred: nothing is specific to the mixture; a prescriber would sensibly watch the sum of the ingredients’ lists: copper status and liver enzymes for GHK-Cu; clotting tests, liver enzymes, glucose and triglycerides for BPC-157, from animal signals; cancer history and screening for BPC-157 and TB-500; no marker at all for KPV.
What nobody knows: whether the four interact in the body or in the vial, whether any amount does anything in a person, and what amount would be harmful.
What common protocols get wrong
- A schedule nobody tested is repeated until it looks established. The stepped schedule appears in near-identical form on two pages, in part on a third and in syringe units on a fourth, which suggests one source copied between sites (our inference).
- Extrapolating from doses nobody tested. The dosing website says its figures “are extrapolated from individual-component research and community protocols”. Under the skin, none of the four given alone has a dose tested in people, and KPV has none by any route.
A dose is a prescriber’s decision for one patient. For this blend there is no study in people to base one on.
Safety, and who should be most cautious
No safety study of the blend exists, in people or in animals, and no toxicology study has given any two of the four together. With four agents in one injection, a reaction cannot be traced to one of them. The blend also includes KPV, which no published study has given to a person and which has no toxicology studies of any kind, and GHK-Cu by injection, which no study in people has given alone.
Reported in people. A report to the FDA does not show that a product caused an event. No report in the FDA’s public data names KLOW or KPV. Two reports of serious events list some of these peptides as taken alongside the suspect drugs, not as suspects. The FDA’s review of BPC-157 describes a woman using a “research purposes only” BPC-157 and TB-500 product who “developed diffuse hyperpigmentation and gingival darkening” (darkened skin and gums) that returned when she used it again; the FDA found it “unclear whether these AEs were attributable to BPC-157” (AEs: adverse events).
The pilot of BPC-157 with thymosin beta-4 reports “No serious adverse events” in its five treated patients and one “asymptomatic, self-resolving ALT rise” (ALT: a liver enzyme). Its table lists injection-site redness or itch in 3, hardening at the site in 2, passing lightheadedness after injection in 2 and headache in 1; its abstract counts redness in 6, more than were injected. The paper says “anti-drug antibody titres were not measured”. In a preprint (not peer reviewed) of Reddit posts about BPC-157 and TB-500, “27.2% described at least one side effect, most often fatigue, anxiety, anhedonia and insomnia”.
The FDA’s concerns. The FDA’s safety-risks page states one for each ingredient. Injectable GHK-Cu “may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities” (an immune reaction to the peptide; molecules clumping together). On KPV: “FDA lacks important information regarding any safety issues raised by KPV”. Of BPC-157 it says it “lacks sufficient information to know whether the drug would cause harm when administered to humans”, and of TB-500 that it “has not identified any human exposure data”.
Theory. On theory alone, people with cancer now or in the past, and people with Wilson disease or another copper disorder, have the most reason for caution. Three of the four (GHK-Cu, BPC-157 and the TB-500 sequence) are credited with promoting new blood-vessel growth in lab or animal studies, and tumours need new vessels to grow; no case of cancer in a person has been attributed to any of them in the sources read, and whether three together change the risk is untested. GHK-Cu, the largest ingredient in the composition most pages give, carries copper, and injected copper bypasses the gut’s control of how much the body takes up.
| Situation | What is known | Basis |
|---|---|---|
| Pregnancy and breastfeeding | No data for the blend, or for any ingredient by injection | No published studies in people |
| Children, older adults, liver or kidney disease | Nothing is known | No study of the blend |
| Cancer, now or in the past | No data in people | Theory |
| Wilson disease or another copper disorder | No GHK-Cu study included such patients | Theory |
Product quality
No independent analysis. We found no published analysis of a KLOW vial, or of any vial holding GHK-Cu with another peptide. The one large analysis of single peptides, a 2026 preprint (not peer reviewed; abstract read) of “6441 peptide samples across fourteen compounds”, found that “41.6% to 71.1% of samples failed to meet basic quality criteria, and measurable endotoxin contamination was present in 15% of samples” (endotoxin: a bacterial toxin). Its authors call those failure rates “a lower bound”. KPV was not among the fourteen, and the abstract names no blend. For KPV, BPC-157 and TB-500, the FDA found certificates of analysis that gave purity and little else.
Recalls. No recall names KLOW. Three recalls name compounded two-peptide injectable vials, among them “BPC-157/KPV 5/5MG/ML (MDV)” in October 2026 for “Lack of Processing Controls”, and single-ingredient injectable GHK-Cu has been recalled three times.
Four peptides in one solution. Nothing has been published on the stability or compatibility of these four together. A 2026 review of GHK-Cu formulation lists “metal exchange with competing ligands” among the changes a developer should assume and test for; whether copper ends up shared with the other peptides in a mixed vial is our inference, plausible and unmeasured.
“Research use only”. None of twelve FDA warning letters about peptide products that we opened names KLOW or its ingredients; the search is not exhaustive. Three cite other multi-peptide vials, sold as “research” products, as unapproved new drugs. In one, the FDA wrote that despite such labels, “evidence obtained from your website establishes that your products are intended to be drugs for human use.” Another says of injectable products sold this way that they “bypass some of the body’s key defenses against toxins and microorganisms”.
What we make of it
This section is our reading of the evidence. It is a judgment, not a finding.
As a blend, KLOW is untested: unproven and experimental, with everything said for it borrowed from its ingredients. Those ingredients are not inert: three of them are credited with promoting blood-vessel growth in lab or animal studies, and if their effects add up anywhere, that is the likeliest place. Plausible is not shown, and the reasoning that predicts added benefit predicts added risk.
“Synergy” is the blend’s selling point and its least supported claim: the only test of a pair against its parts, in rats, found no added benefit. In our reading, four peptides in one vial make each open question harder to answer: an effect or a side effect can’t be traced to one ingredient, no ingredient can be adjusted or stopped alone, the mixture’s chemistry is unstudied, and one of the four has never been given to a person in a published study.
Three things would have to be shown: that the four stay stable together in one solution; that the mixture does something in people that its parts do not; and that it is safe at the exposure used.
Whether a blend like this has a place in anyone’s care, for whom, after what, with what monitoring and when to stop are our Medical Director’s to state.
Peptide care at Rock Creek Wellness
Our peptide care starts with lab tests and a visit with one of our providers. The provider decides whether any peptide suits you, and which one; you don’t choose from a menu. How that care works is set out on our peptide therapy page, along with the other reviews in this library. What Peptide Care costs is on the same page.
So that you can weigh this review knowing our interest: RCW’s providers prescribe some of the peptides reviewed in this library, and RCW earns money from that care.
What would change this review
- A study of the blend itself. ClinicalTrials.gov listed no trial of KLOW, or of any two of its ingredients together, on November 19, 2026.
- Stability data for the four in one solution.
- A first study in people of KPV, and of injected GHK-Cu given alone.
- A controlled comparison in people of any two of the four with each given alone.
- Rulemaking: a final rule on any of the four, or the FDA’s advisory committee meeting on GHK-Cu, planned before the end of February 2027.
Common questions
Does KLOW work?
Nobody knows: the blend has not been tested in people, in animals or in cells. Its ingredients have their own research, mostly in animals and cells, and the one animal study of two of them together found no added benefit.
Is KLOW safe?
That is unknown. No safety study of the blend exists, KPV has no published study in people, and the FDA has stated a safety concern about each of the four.
Is KLOW FDA-approved?
No. Neither the blend nor any of its four ingredients is an FDA-approved drug. HHS’s draft policy on compounding is not an approval, and it applies only to single-ingredient products.
Can a doctor prescribe KLOW?
The FDA and HHS documents we read give no yes or no about prescribers: their conditions attach to the compounding and to the product, not to the writing of a prescription. Any prescription would be for a compounded medicine, and a compounded injection that combines these peptides is outside both agencies’ policies. State pharmacy rules apply separately.
How much KLOW do people take, and how often?
No amount or schedule has been tested in people. Sellers’ pages and dosing websites most often describe one injection under the skin a day, at about 2 to 6 mg of total blend; that is practice no trial set. No half-life has been measured in people for any of the four, so nothing measured fixes how often it would be given.
Sources
Show all 29 sourcesHide sources
- HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. US Department of Health and Human Services, 2026.
- Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (notice of availability, 91 FR 68526, FR Doc. 2026-22192). Federal Register, 2026.
- Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act. US Food and Drug Administration, 2025.
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (category list). US Food and Drug Administration, 2026.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. US Food and Drug Administration, 2026.
- FDA Briefing Document: BPC-157-Related Bulk Drug Substances (BPC-157 (free base) and BPC-157 acetate), Pharmacy Compounding Advisory Committee, July 23-24, 2026. US Food and Drug Administration, 2026.
- FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026: FDA Evaluation of KPV-Related Bulk Drug Substances (KPV (Free Base) and KPV acetate). US Food and Drug Administration, 2026.
- FDA Briefing Document, Pharmacy Compounding Advisory Committee: Evaluation of TB-500-related Bulk Drug Substances (TB-500 (free base) and TB-500 acetate) for Inclusion on the 503A Bulk Drug Substances List. US Food and Drug Administration, 2026.
- Meeting of the Pharmacy Compounding Advisory Committee (before the end of February 2027). US Food and Drug Administration, 2026.
- openFDA drug enforcement (recall) data. US Food and Drug Administration, 2026.
- openFDA drug adverse event (FAERS) data, report 26810736. US Food and Drug Administration, 2026.
- openFDA drug adverse event (FAERS) data, report 25484639. US Food and Drug Administration, 2026.
- Warning letter: Royal Peptides LLC, MARCS-CMS 734884. US Food and Drug Administration, 2026.
- Warning letter: NuScience Peptides LLC, MARCS-CMS 733652. US Food and Drug Administration, 2026.
- Warning letter: PekCura Labs, MARCS-CMS 721709. US Food and Drug Administration, 2026.
- WADA 2026 Prohibited List; WADA 2027 Prohibited List; Summary of Major Modifications and Explanatory Notes, 2027 Prohibited List. World Anti-Doping Agency, 2025 and 2026.
- ClinicalTrials.gov. US National Library of Medicine, searched 2026.
- PubMed. US National Library of Medicine, searched 2026.
- Europe PMC. EMBL-EBI, searched 2026.
- Adjunctive Weekly Subcutaneous Thymosin β4 and BPC-157 With Intensive Rehabilitation in Subacute AIS-B Thoracic Spinal Cord Injury: A 6-Month Open-Label Controlled Pilot Study. American Journal of Medical and Clinical Research & Reviews, 2026.
- Thymosin β4 and BPC-157 as Candidate Regenerative Peptide Therapies for Spinal Cord Injury: Mechanisms, Preclinical Evidence, and First Clinical Signals. Preprints.org (preprint, not peer reviewed), 2026.
- Case Report: Regenerative peptides for Inferior alveolar nerve injury: a narrative review with hypothesis-generating three clinical cases. Frontiers in Oral Health, 2026.
- Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative Therapies in Health and Medicine, 2021.
- Real-World Use, Dosing, and Reported Side Effects of BPC-157 and TB-500 for Musculoskeletal Injury: An Analysis of Online Communities. medRxiv (preprint, not peer reviewed), 2026.
- Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Joint Diseases and Related Surgery, 2026.
- Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Frontiers in Pharmacology, 2022.
- Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography-mass spectrometry. Journal of Chromatography A, 2012.
- Evaluation of Research Grade Peptides Marketed Directly to Consumers Reveals Extensive Variability in Purity and Measured Abundance. Preprints.org (preprint, not peer reviewed), 2026.
- GHK-Cu as a Bioactive Metallopeptide and Drug-Delivery Cargo: Coordination Chemistry, Formulation Science, Therapeutic Evidence, and a Translational Roadmap. Pharmaceutics, 2026.
